Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlberto, Matthew-
dc.contributor.authorYim, Arthur-
dc.contributor.authorPapa, Nathan-
dc.contributor.authorSiva, Shankar-
dc.contributor.authorIschia, Joseph J-
dc.contributor.authorTouijer, Karim-
dc.contributor.authorEastham, James A-
dc.contributor.authorBolton, Damien M-
dc.contributor.authorPerera, Marlon-
dc.identifier.citationFrontiers in Oncology 2022; 12: 929444en_US
dc.description.abstractOligometastatic prostate cancer (OMPC) has been proposed as an intermediary state between localised disease and widespread metastases, with varying definitions including 1, 3, or ≤5 visceral or bone metastasis. Traditional definitions of OMPC are based on staging with conventional imaging, such as computerised tomography (CT) and whole-body bone scan (WBBS). Novel imaging modalities such as prostate-specific membrane antigen positron emission tomography (PSMA PET) have improved diagnostic utility in detecting early metastatic prostate cancer (PC) metastases compared with conventional imaging. Specifically, meta-analytical data suggest that PSMA PET is sensitive in detecting oligometastatic disease in patients with biochemical recurrence (BCR) post-radical treatment of PC. Recent trials have evaluated PSMA PET-guided metastases-directed therapy (MDT) in oligometastatic recurrent disease, typically with salvage surgery or radiotherapy (RT). To date, these preliminary studies demonstrate promising results, potentially delaying the need for systemic therapy. We aim to report a comprehensive, multidisciplinary review of PSMA-guided MDT in OMPC. In this review, we highlight the utility of PMSA PET in biochemically recurrent disease and impact of PSMA PET on the definition of oligometastatic disease and outline data pertaining to PSMA-guided MDT.en_US
dc.subjectPSMA PETen_US
dc.subjectmetastastases directed therapyen_US
dc.subjectmetastatic diseaseen_US
dc.subjectprostate canceren_US
dc.titleRole of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleFrontiers in Oncologyen_US
dc.identifier.affiliationUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.en_US
dc.identifier.affiliationDepartment of Preventive Medicine, Monash University, Melbourne, VIC, Australiaen_US
dc.identifier.affiliationDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australiaen_US
dc.identifier.affiliationSurgery (University of Melbourne)en_US
dc.identifier.pubmedid36059632, Damien M
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Sep 26, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.